Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
NCT02956382Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Mar 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib and venetoclax in follicular lymphoma (FL) (5 arms), sponsored by Georgetown University. Primary endpoints: Recommended Phase 2 Dose at 28 days and Overall Response Rate at 36 months. Started Mar 2017; status: completed.
02
Drugs
ibrutinibvenetoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02956382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956382.